Journal of Hepatology
Volume 52, Issue 5 , Pages 771-775 , May 2010

Personalized molecular targeted therapy in advanced, recurrent hepatocellular carcinoma after liver transplantation: A proof of principle

  • Sherrie Bhoori

      Affiliations

    • Liver Unit, Hepato-Oncology Group and Molecular Pathology, National Cancer Institute (Fondazione Istituto Nazionale Tumori), Milan, Italy
    • ,
  • Sara Toffanin

      Affiliations

    • Liver Unit, Hepato-Oncology Group and Molecular Pathology, National Cancer Institute (Fondazione Istituto Nazionale Tumori), Milan, Italy
    • Mount Sinai Liver Cancer Program, Division of Liver Diseases, Mount Sinai School of Medicine, New York, USA
    • ,
  • Carlo Sposito

      Affiliations

    • Liver Unit, Hepato-Oncology Group and Molecular Pathology, National Cancer Institute (Fondazione Istituto Nazionale Tumori), Milan, Italy
    • ,
  • Alessandro Germini

      Affiliations

    • Liver Unit, Hepato-Oncology Group and Molecular Pathology, National Cancer Institute (Fondazione Istituto Nazionale Tumori), Milan, Italy
    • ,
  • Alessandro Pellegrinelli

      Affiliations

    • Liver Unit, Hepato-Oncology Group and Molecular Pathology, National Cancer Institute (Fondazione Istituto Nazionale Tumori), Milan, Italy
    • ,
  • Andrea Lampis

      Affiliations

    • Liver Unit, Hepato-Oncology Group and Molecular Pathology, National Cancer Institute (Fondazione Istituto Nazionale Tumori), Milan, Italy
    • ,
  • Vincenzo Mazzaferro

      Affiliations

    • Liver Unit, Hepato-Oncology Group and Molecular Pathology, National Cancer Institute (Fondazione Istituto Nazionale Tumori), Milan, Italy
    • Corresponding Author InformationCorresponding author. Address: Gastro-Intestinal Surgery and Liver Transplantation, Istituto Nazionale Tumori, Via Venezian 1, Milan 20133, Italy. Tel.: +39 02 23902760; fax: +39 02 23903259.

Received 23 November 2009 ,Revised 12 January 2010 ,Accepted 18 January 2010.

References 

  1. Aravalli RN, Steer CJ, Cressman EN. Molecular mechanisms of hepatocellular carcinoma. Hepatology. 2008;48:2047–2063
  2. Thomas M. Molecular targeted therapy for hepatocellular carcinoma. J Gastroenterol. 2009;44:136–141
  3. Chiang DY, Villanueva A, Hoshida Y, Peix J, Newell P, Minguez B, et al. Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res. 2008;68:6779–6788
  4. Bioulac-Sage P, Rebouissou S, Thomas C, Blanc JF, Saric J, Sa Cunha A, et al. Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry. Hepatology. 2007;46:740–748
  5. Villanueva A, Toffanin S, Llovet JM. Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps. Curr Opin Oncol. 2008;20:444–453
  6. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208–1236
  7. Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48, 900 necropsies. Cancer. 1954;7:462–503
  8. International Consensus Group for Hepatocellular Neoplasia. The International Consensus Group for Hepatocellular Neoplasia. Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology 2009;49:658–64.
  9. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22:696–699
  10. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The Metavir Cooperative Study Group. Hepatology. 1996;24:289–293
  11. National Cancer Institute. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Available from: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf [accessed on 10.01.09].
  12. Signoroni S, Frattini M, Negri T, Pastore E, Tamborini E, Casieri P, et al. Cyclooxygenase-2 and platelet-derived growth factor receptors as potential targets in treating aggressive fibromatosis. Clin Cancer Res. 2007;13:5034–5040Erratum in: Clin Cancer Res. 2008;14:4354
  13. Villanueva A, Chiang DY, Newell P, Peix J, Thung S, Alsinet C, et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology. 2008;135:1972–1983
  14. Newell P, Toffanin S, Villanueva A, Chiang DY, Minguez B, Cabellos L, et al. Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. J Hepatol. 2009;51:725–733
  15. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008;100:698–711
  16. Boyault S, Rickman DS, De Reyniès A, Balabaud C, Rebouissou S, Jeannot E, et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology. 2007;45:42–52
  17. Takigawa Y, Brown AM. Wnt signaling in liver cancer. Curr Drug Targets. 2008;9:1013–1024
  18. Schreibman IR, Bejarano P, Martinez EJ, Regev A. Very late recurrence of hepatocellular carcinoma after liver transplantation: case report and literature review. Transplant Proc. 2006;38:3140–3143
  19. Chiba T, Kamiya A, Yokosuka O, Iwama A. Cancer stem cells in hepatocellular carcinoma: recent progress and perspective. Cancer Lett. 2009;286:145–153
  20. Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. Oncogene. 2007;26:3279–3290
  21. Zhang Z, Zhou X, Shen H, Wang D, Wang Y. Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitro study. BMC Med. 2009;7:40–52
  22. Vinciguerra M, Sgroi A, Veyrat-Durebex C, Rubbia-Brandt L, Buhler LH, Foti M. Unsaturated fatty acids inhibit the expression of tumor suppressor phosphatase and tensin homolog (PTEN) via microRNA-21 up-regulation in hepatocytes. Hepatology. 2009;49:1176–1184
  23. Semela D, Piguet AC, Kolev M, Schmitter K, Hlushchuk R, Djonov V, et al. Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma. J Hepatol. 2007;46:840–848
  24. Wang Z, Zhou J, Fan J, Qiu SJ, Yu Y, Huang XW, et al. Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma. Clin Cancer Res. 2008;14:5124–5130
  25. Carracedo A, Baselga J, Pandolfi PP. Deconstruction feed-back signaling networks to improve anticancer therapy with mTORC1 inhibitors. Cell Cycle. 2008;7:3805–3809
  26. Piguet AC, Semela D, Keogh A, Wilkens L, Stroka D, Stoupis C, et al. Inhibition of mTOR in combination with doxorubicin in an experimental model of hepatocellular carcinoma. J Hepatol. 2008;49:78–87
  27. Huynh H, Chow PK, Palanisamy N, Salto-Tellez M, Goh BC, Lee CK, et al. Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. J Hepatol. 2008;49:52–60

PII: S0168-8278(10)00079-6

doi: 10.1016/j.jhep.2010.01.025

Journal of Hepatology
Volume 52, Issue 5 , Pages 771-775 , May 2010

Article Tools

* Image Usage & Resolution